Bright Minds Biosciences has announced the commencement of the Phase II BREAKTHROUGH clinical trial of BMB-101, targeting adult patients with classic absence epilepsy and developmental epileptic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results